



Nurix Therapeutics to Participate in Upcoming Investor Conferences

February 8, 2023

SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, and Gwenn M. Hansen, Ph.D., Nurix's chief scientific officer, will participate in the following conferences in February:

- **SVB Securities Global Biopharma Conference (Virtual)**

Fireside chat: Wednesday, February 15, 4:20 – 5:00 p.m. ET

Speaker: Arthur T. Sands, M.D., Ph.D.

- **Wells Fargo Targeted Protein Degradation Virtual Summit**

Tuesday, February 21

- Panel Topic: *Overcoming Resistance with Targeted Protein Degradation*

- 8:00 – 8:45 a.m. ET

- Panelist: Arthur T. Sands, M.D., Ph.D.

- Panel Topic: *Degradation vs. Inhibition – When Does Targeted Protein Degradation Make Sense and When Does It Not?*

- 1:00 – 1:45 p.m. ET

- Panelist: Gwenn M. Hansen, Ph.D.

The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. Archived copies of the webcasts will be available on the Nurix website for approximately 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit <http://www.nurixtx.com>.

Contacts:

Investors

Silinda Neou

Nurix Therapeutics

ir@nurixtx.com

Elizabeth Wolffe, Ph.D.

Wheelhouse Life Science Advisors

lwolffe@wheelhousesa.com

Media

Aljanae Reynolds

Wheelhouse Life Science Advisors

areynolds@wheelhousesa.com